Taysha Gene Therapies Stock In The News
| TSHA Stock | USD 3.24 0.24 8.00% |
Our overall analysis of Taysha Gene's news coverage and content from conventional and social sources shows investors' bearish mood towards Taysha Gene Therapies. The specific impact of Taysha Gene news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Taysha Gene's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Taysha Gene headlines in addition to utilizing other, more conventional financial analysis modules. Check out Taysha Gene Backtesting and Taysha Gene Hype Analysis.
Taysha |
Taysha Gene Today Top News and Investor Outlook
Taysha Gene Therapies Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Taysha and other traded companies coverage with news coverage. We help investors stay connected with Taysha headlines for the 2nd of December to make an informed investment decision based on correlating the impacts of news items on Taysha Stock performance. Please note that trading solely based on the Taysha Gene Therapies hype is not for everyone as timely availability and quick action are needed to avoid losses.
Taysha Gene stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Taysha earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Taysha Gene that are available to investors today. That information is available publicly through Taysha media outlets and privately through word of mouth or via Taysha internal channels. However, regardless of the origin, that massive amount of Taysha data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Taysha Gene news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Taysha Gene relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Taysha Gene's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Taysha Gene alpha.
Taysha Largest EPS Surprises
Earnings surprises can significantly impact Taysha Gene's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.09 | -0.0712 | 0.0188 | 20 | ||
2023-11-14 | 2023-09-30 | -0.17 | -0.13 | 0.04 | 23 | ||
2024-08-12 | 2024-06-30 | -0.16 | -0.09 | 0.07 | 43 | ||
2023-08-14 | 2023-06-30 | -0.31 | -0.38 | -0.07 | 22 | ||
2023-05-11 | 2023-03-31 | -0.35 | -0.28 | 0.07 | 20 | ||
2022-08-11 | 2022-06-30 | -1 | -0.84 | 0.16 | 16 |
Taysha Gene Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Taysha Gene Therapies Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
21st of November 2024
104,535 Shares in Terns Pharmaceuticals, Inc. Purchased by Quest Partners LLC - MarketBeat at news.google.com
20th of November 2024
Citigroup Downgrades Shattuck Labs - MSN at news.google.com
20th of November 2024
ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN at news.google.com
19th of November 2024
X4 Pharmaceuticals CEO Ragan Paula sells 12,583 in stock - Investing.com at news.google.com
18th of November 2024
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Explor... at gurufocus.com
15th of November 2024
Redmile Group, LLC Adjusts Stake in Stoke Therapeutics Inc - GuruFocus.com at news.google.com
15th of November 2024
Wall Street Analysts Think Monte Rosa Therapeutics Could Surge 100.47 percent Read This Be... at zacks.com
15th of November 2024
C4 Therapeutics, Inc.s 33 percent Share Price Plunge Could Signal Some Risk at simplywall.st
14th of November 2024
After Plunging -15.92 percent in 4 Weeks, Heres Why the Trend Might Reverse for Gossamer B... at zacks.com
14th of November 2024
X4 Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strategic Engagement and ... at gurufocus.com
14th of November 2024
Alector Secures Flexible Credit Facility for Up to 50 Million From Hercules Capital at globenewswire.com
12th of November 2024
News Flash Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. Fo... at simplywall.st
11th of November 2024
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635 at businesswire.com
11th of November 2024
Inozyme Pharma to Present at Upcoming Investor Conferences at globenewswire.com
11th of November 2024
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance at zacks.com
7th of November 2024
Acquisition by Ticho Barry of 10000 shares of Stoke Therapeutics at 0.6 subject to Rule 16... at MacroaxisInsider
7th of November 2024
Disposition of 11245 shares by Blackman Samuel C. of Day One at 16.0326 subject to Rule 16... at gurufocus.com
7th of November 2024
Disposition of 12500 shares by Andrew Hirsch of C4 Therapeutics subject to Rule 16b-3 at MacroaxisInsider
6th of November 2024
Alector Q3 Earnings Snapshot at finance.yahoo.com
5th of November 2024
Stoke Therapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates at zacks.com
5th of November 2024
Vanguard Group Incs Strategic Acquisition in Shattuck Labs Inc at gurufocus.com
1st of November 2024
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 at globenewswire.com
1st of November 2024
Iain Ross Buys 1,100,000 Shares of Tern Plc Stock at thelincolnianonline.com
31st of October 2024
Will Monte Rosa continue to dip in December at Macroaxis
31st of October 2024
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlight... at globenewswire.com
30th of October 2024
SUNDECK 3200 HERALDS IN A NEW DAWN FOR HURRICANE BOATS at prnewswire.com
28th of October 2024
Monte Rosa jumps on 150M license deal with Novartis at seekingalpha.com
24th of October 2024
Down -64.19 percent in 4 Weeks, Heres Why Shattuck Labs Looks Ripe for a Turnaround at finance.yahoo.com
22nd of October 2024
Dawn Protocol Hits Market Capitalization of 167,632.91 at thelincolnianonline.com
17th of October 2024
Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the ... at finance.yahoo.com
16th of October 2024
Shareholders that Lost Money on Shattuck Labs, Inc. Should Contact Levi Korsinsky About Se... at accesswire.com
14th of October 2024
Crypto Content Creator Campus prsentiert hochkartige Referenten fr die Erffnungsveranstalt... at prnewswire.com
10th of October 2024
Acquisition by Kenkare-mitra Sara of 163600 shares of Alector subject to Rule 16b-3 at MacroaxisInsider
7th of October 2024
Disposition of 76920 shares by Arthur Taveras of X4 Pharmaceuticals at 0.563 subject to Ru... at MacroaxisInsider
7th of October 2024
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5... at finance.yahoo.com
2nd of October 2024
Stoke therapeutics executive sells 120k in stock at investing.com
30th of September 2024
Gossamer Bio, Inc. Short Interest Down 5.8 percent in September - MarketBeat at news.google.com
24th of September 2024
Samlyn Capital LLC Has 14.94 Million Stock Position in Inozyme Pharma, Inc. - MarketBeat at news.google.com
20th of September 2024
Disposition of tradable shares by Emily Pimblett of Eliem Therapeutics at 8.06 subject to ... at MacroaxisInsider
19th of September 2024
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Co... at finance.yahoo.com
11th of September 2024
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation S... at finance.yahoo.com
6th of July 2023
GenScript Doubles cGMP sgRNA and Non-Viral DNA Payload Manufacturing Capacity - Yahoo Fina... at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Taysha Gene in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Taysha Gene's short interest history, or implied volatility extrapolated from Taysha Gene options trading.
Check out Taysha Gene Backtesting and Taysha Gene Hype Analysis. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share 0.042 | Quarterly Revenue Growth (0.62) | Return On Assets (0.27) | Return On Equity (1.15) |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.